Organisation paid for research Program year 2025 Source: CMS Open Payments

Newportnativemd Inc

Neither a doctor nor a teaching hospital

Research payments

$1,668,889

293 payments

Through program year 2025, Newportnativemd Inc is reported as receiving $1,668,889 in research payments, across 293 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $629,160 122
2024 Research $356,086 70
2023 Research $254,006 39
2022 Research $155,561 18
2021 Research $116,969 21
2020 Research $65,107 17
2019 Research $91,999 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $483,034 23 payments
  2. United Therapeutics Corporation $278,447 68 payments
  3. GlaxoSmithKline, LLC. $215,939 48 payments
  4. Sanofi US Services Inc. $184,961 27 payments
  5. Novartis Pharmaceuticals Corporation $126,227 11 payments
  6. Genentech, Inc. $100,812 24 payments
  7. Chiesi USA, Inc. $78,122 24 payments
  8. Genzyme Corporation $65,012 19 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $57,961 3 payments
  10. Amgen Inc. $55,116 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. CatC inhibitor Phase II in bronchiectasis $261,126 8 payments
  2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $130,059 32 payments
  3. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $110,792 20 payments
  4. A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (AirleafTM) $100,879 1 payment
  5. Roche Cancer Screening Collection Study $100,812 24 payments
  6. A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) $81,778 12 payments
  7. A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) $72,663 47 payments
  8. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $70,376 12 payments
  9. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $69,262 21 payments
  10. An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $66,609 24 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record